ITHACA, N.Y. – Rheonix Inc., developer of automated molecular diagnostic platforms and consumables, has appointed Bill Colston, Ph.D., to its board of directors. Colston, former CEO of QuantaLife Inc., led the development and product launch of Droplet Digital PCR™, a genetic analysis system for quantifying DNA molecules, until his company was acquired by Bio-Rad Laboratories in 2011.
As QuantaLife CEO, Colston raised multiple rounds of private funding and grew the company from four founders in 2008 to more than 60 employees by 2011. The company was unanimously selected as the “Most Promising Company” at the Personalized Medicine World Conference in 2010. Before founding QuantaLife in 2008, Colston had a 19-year career at Lawrence Livermore National Laboratory, advancing from scientist to program manager directing a $160 million annual budget and 400 employees.
“I am excited to join the board of a company that aligns so well to my interests in growing organizations in medical devices, life sciences and diagnostics,” said Colston. “With the Rheonix CARD® technology providing an economical solution to the molecular diagnostic market and beyond, Rheonix is poised to make a big impact on the diagnostics industry.”
“Dr. Colston brings to Rheonix invaluable experience in building and exiting market-meaningful technology platforms via startup companies,” said Rheonix President Tony Eisenhut. “Rheonix is at an important inflection point in our business. We are navigating a transition from a small number of installed platforms to more widespread adoption of the EncompassMDx™ in the clinical and environmental testing arenas. Bill successfully led QuantaLife through a similar transition by successfully introducing disruptive technology to the market. With this experience, he can help guide our way in his capacity as board member.”
Colston earned a Bachelor of Science degree from The University of Texas at Austin and a doctorate in biomedical engineering from University of California, Davis.
Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the Encompass platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy–to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and Encompass family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit www.rheonix.com.
Public Relations Account Manager
Pinckney Hugo Group
760 West Genesee Street
Syracuse, NY 13204